PMID- 26155414
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210112
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 4
IP  - 6
DP  - 2015 Jun
TI  - Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell 
      carcinoma is associated with poor prognosis.
PG  - e1008342
LID - e1008342
AB  - Dendritic cells (DCs) essentially contribute to the induction and regulation of 
      innate and adaptive immunity. Based on these important properties, DCs may 
      profoundly influence tumor progression in patients. However, little is known 
      about the role of distinct human DC subsets in primary tumors and their impact on 
      clinical outcome. In the present study, we investigated the characteristics of 
      human 6-sulfo LacNAc (slan) DCs in clear cell renal cell carcinoma (ccRCC). 
      slanDCs have been shown to display various tumor-directed properties and to 
      accumulate in tumor-draining lymph nodes from patients. When evaluating 263 ccRCC 
      and 227 tumor-free tissue samples, we found increased frequencies of slanDCs in 
      ccRCC tissues compared to tumor-free tissues. slanDCs were also detectable in the 
      majority of 24 metastatic lymph nodes and 67 distant metastases from ccRCC 
      patients. Remarkably, a higher density of slanDCs was significantly associated 
      with a reduced progression-free, tumor-specific or overall survival of ccRCC 
      patients. Tumor-infiltrating slanDCs displayed an immature phenotype expressing 
      interleukin-10. ccRCC cells efficiently impaired slanDC-induced T-cell 
      proliferation and programming as well as natural killer (NK) cell activation. In 
      conclusion, these findings indicate that higher slanDC numbers in ccRCC tissues 
      are associated with poor prognosis. The induction of a tolerogenic phenotype in 
      slanDCs leading to an insufficient activation of innate and adaptive antitumor 
      immunity may represent a novel immune escape mechanism of ccRCC. These 
      observations may have implications for the design of therapeutic strategies that 
      harness tumor-directed functional properties of DCs against ccRCC.
FAU - Toma, Marieta
AU  - Toma M
AD  - Institute of Pathology; University Hospital of Dresden ; Dresden, Germany.
FAU - Wehner, Rebekka
AU  - Wehner R
AD  - Institute of Immunology; Medical Faculty; TU Dresden ; Dresden, Germany.
FAU - Kloss, Anja
AU  - Kloss A
AD  - Institute of Immunology; Medical Faculty; TU Dresden ; Dresden, Germany.
FAU - Hubner, Linda
AU  - Hubner L
AD  - Institute of Immunology; Medical Faculty; TU Dresden ; Dresden, Germany.
FAU - Fodelianaki, Georgia
AU  - Fodelianaki G
AD  - Institute of Immunology; Medical Faculty; TU Dresden ; Dresden, Germany ; Center 
      for Regenerative Therapies Dresden ; Dresden, Germany.
FAU - Erdmann, Kati
AU  - Erdmann K
AD  - Department of Urology; University Hospital of Dresden ; Dresden, Germany.
FAU - Fussel, Susanne
AU  - Fussel S
AD  - Department of Urology; University Hospital of Dresden ; Dresden, Germany.
FAU - Zastrow, Stefan
AU  - Zastrow S
AD  - Department of Urology; University Hospital of Dresden ; Dresden, Germany.
FAU - Meinhardt, Matthias
AU  - Meinhardt M
AD  - Institute of Pathology; University Hospital of Dresden ; Dresden, Germany.
FAU - Seliger, Barbara
AU  - Seliger B
AD  - Institute for Medical Immunology; Martin Luther University Halle-Wittenberg ; 
      Halle (Saale), Germany.
FAU - Brech, Dorothee
AU  - Brech D
AD  - Institute of Molecular Immunology; Helmholtz Center Munich; German Research 
      Center for Environmental Health Munich ; Munich, Germany.
FAU - Noessner, Elfriede
AU  - Noessner E
AD  - Institute of Molecular Immunology; Helmholtz Center Munich; German Research 
      Center for Environmental Health Munich ; Munich, Germany.
FAU - Tonn, Torsten
AU  - Tonn T
AD  - Center for Regenerative Therapies Dresden ; Dresden, Germany ; German Red Cross 
      Blood Service ; Dresden, Germany ; German Cancer Consortium (DKTK) ; Dresden, 
      Germany ; German Cancer Research Center (DKFZ) ; Heidelberg, Germany.
FAU - Schakel, Knut
AU  - Schakel K
AD  - Department of Dermatology; University Hospital of Heidelberg ; Heidelberg, 
      Germany.
FAU - Bornhauser, Martin
AU  - Bornhauser M
AD  - Center for Regenerative Therapies Dresden ; Dresden, Germany ; German Cancer 
      Consortium (DKTK) ; Dresden, Germany ; German Cancer Research Center (DKFZ) ; 
      Heidelberg, Germany ; Department of Medicine I; University Hospital of Dresden ; 
      Dresden, Germany.
FAU - Bachmann, Michael P
AU  - Bachmann MP
AD  - Center for Regenerative Therapies Dresden ; Dresden, Germany ; German Cancer 
      Consortium (DKTK) ; Dresden, Germany ; German Cancer Research Center (DKFZ) ; 
      Heidelberg, Germany ; Department of Radioimmunology; Institute of 
      Radiopharmaceutical Cancer Research; Helmholtz Center Dresden-Rossendorf ; 
      Dresden, Germany.
FAU - Wirth, Manfred P
AU  - Wirth MP
AD  - Department of Urology; University Hospital of Dresden ; Dresden, Germany ; German 
      Cancer Consortium (DKTK) ; Dresden, Germany ; German Cancer Research Center 
      (DKFZ) ; Heidelberg, Germany.
FAU - Baretton, Gustavo
AU  - Baretton G
AD  - Institute of Pathology; University Hospital of Dresden ; Dresden, Germany ; 
      German Cancer Consortium (DKTK) ; Dresden, Germany ; German Cancer Research 
      Center (DKFZ) ; Heidelberg, Germany.
FAU - Schmitz, Marc
AU  - Schmitz M
AD  - Institute of Immunology; Medical Faculty; TU Dresden ; Dresden, Germany ; Center 
      for Regenerative Therapies Dresden ; Dresden, Germany ; German Cancer Consortium 
      (DKTK) ; Dresden, Germany ; German Cancer Research Center (DKFZ) ; Heidelberg, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150302
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC4485722
OTO - NOTNLM
OT  - CTLs, cytotoxic T cells
OT  - DCs, dendritic cells
OT  - FCS, fetal calf serum
OT  - HLA, human leukocyte antigen
OT  - IFNgamma, interferongamma
OT  - IL, interleukin
OT  - ILT, immunoglobulin-like transcript
OT  - LPS, lipopolysaccharide
OT  - NK cells, natural killer cells
OT  - PBMCs, peripheral blood mononuclear cells
OT  - PMA, phorbol myristate acetate
OT  - T cells
OT  - TMAs, tissue microarrays
OT  - TNF-alpha, tumor necrosis factor-alpha
OT  - Th1 cells, T helper type I cells
OT  - ccRCC, clear cell renal cell carcinoma
OT  - dendritic cells
OT  - renal cell carcinoma
OT  - slan, 6-sulfo LacNAc
OT  - tumor immunology
OT  - tumor microenvironment
EDAT- 2015/07/15 06:00
MHDA- 2015/07/15 06:01
PMCR- 2016/03/02
CRDT- 2015/07/09 06:00
PHST- 2014/11/17 00:00 [received]
PHST- 2015/01/07 00:00 [revised]
PHST- 2015/01/08 00:00 [accepted]
PHST- 2015/07/09 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/07/15 06:01 [medline]
PHST- 2016/03/02 00:00 [pmc-release]
AID - 1008342 [pii]
AID - 10.1080/2162402X.2015.1008342 [doi]
PST - epublish
SO  - Oncoimmunology. 2015 Mar 2;4(6):e1008342. doi: 10.1080/2162402X.2015.1008342. 
      eCollection 2015 Jun.